This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Nelson syndrome / Post-adrenalectomy ACTH hypersecretion넬슨증후군 (부신절제술 후 ACTH 과분비증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: E24.1 (Nelson syndrome) | Special Copayment Reduction: V114 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsPost-adrenalectomy pituitary tumor, Post-bilateral adrenalectomy ACTH hypersecretion, Nelson-Salassa syndrome
C. Adult onsetLikelihood of first onset in adulthood very high — appears on average 1–3 years later in adult patients who underwent bilateral adrenalectomy for Cushing disease. Can also occur after adrenalectomy in children.
1. HistoryIn 1958 Don H. Nelson first described cases of pituitary adenoma growth and skin hyperpigmentation after bilateral adrenalectomy → proposed loss of negative feedback as the causal mechanism.
2. CausesLoss of cortisol negative feedback after bilateral adrenalectomy in Cushing disease → rapid growth and increased aggressiveness of the pre-existing ACTH-secreting adenoma → extremely high ACTH and MSH hypersecretion.
3. GeneticsSame somatic mutation background as the underlying Cushing adenoma (USP8 mutations, etc.). Additional genomic instability mutations may be acquired on transition to aggressive growth. No familial inheritance.
4. General epidemiologyIncidence about 8–38% after bilateral adrenalectomy. Higher incidence with adrenalectomy without radiotherapy. Mean time to onset after adrenalectomy 1–4 years.
5. PathophysiologyBilateral adrenalectomy → loss of cortisol secretion → loss of HPA axis negative feedback → release of inhibition of pituitary adenoma cells → CRH hypersecretion (hypothalamus) + autonomous adenoma growth → transformation to macroadenoma and extremely high ACTH and MSH.
6. SymptomsGeneralized skin and mucosal hyperpigmentation (especially palmar creases, gums, scar sites), headache, visual field defects (optic chiasm compression), facial nerve palsy, severe fatigue and weakness. Previous Cushing symptoms disappear (no adrenal glands).
7. SignsSkin and mucosal hyperpigmentation (MSH excess), extremely high plasma ACTH (often >200 pg/mL), visual field defects (perimetry), macroadenoma or invasive adenoma on MRI, findings of optic nerve compression.
8. ScreeningPlasma ACTH measurement every 6 months + annual pituitary MRI in all patients after bilateral adrenalectomy. Early detailed evaluation if ACTH shows a rising trend or skin hyperpigmentation appears.
9. DiagnosisHistory of bilateral adrenalectomy + extremely high plasma ACTH (>200 pg/mL threshold) + confirmation of adenoma growth on pituitary MRI. Visual field testing and ophthalmologic evaluation are mandatory.
10. TreatmentFirst-line: transsphenoidal surgery (tumor removal). If residual after surgery: radiosurgery (Gamma Knife, CyberKnife) or fractionated radiotherapy. Drugs: cabergoline, pasireotide, temozolomide (aggressive adenomas). Prevention: radiotherapy before adrenalectomy.
11. PrognosisPoor prognosis because of a frequently aggressive course. Remission is possible after surgery, but the risk of recurrence is high. Risk of neurological complications such as vision loss. Prognosis improves with early detection and treatment.
12. PreventionPituitary radiotherapy before bilateral adrenalectomy to suppress adenoma growth. Early detection through regular ACTH and MRI follow-up after adrenalectomy. First-line treatment of Cushing disease (transsphenoidal surgery) is the best prevention.
13. ReferencesNelson DH, Meakin JW, Thorn GW. ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome. 1960 … and 9 other papers

1. History

The history of Nelson syndrome is inseparably linked to the history of treatment of Cushing disease. Until the early 1950s, the standard treatment for Cushing disease was not direct removal of the causative pituitary adenoma but bilateral adrenalectomy, which removes the target organ, the adrenal glands themselves. This surgery was an effective way to immediately end cortisol hypersecretion, but it carried the permanent consequence of adrenal insufficiency and the seeds of an unexpected new complication.

In 1958, the American endocrinologist Don H. Nelson and his colleagues James W. Meakin and George W. Thorn published in Annals of Internal Medicine a case report describing rapid growth of pituitary tumors and generalized hyperpigmentation in patients with Cushing disease who had undergone bilateral adrenalectomy. In this paper, Nelson et al. explained that after adrenalectomy, the pituitary ACTH-secreting adenoma, having lost negative feedback inhibition by cortisol, grows autonomously and develops into a macroadenoma, and that together with this, extremely high secretion of ACTH and melanocyte-stimulating hormone (MSH) causes skin hyperpigmentation. This clinical syndrome was named after them as 'Nelson syndrome' or 'Nelson-Salassa syndrome'.

In 1960, after analyzing more cases, Nelson et al. published a follow-up paper, "ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome", in Annals of Internal Medicine, further consolidating the clinical entity of this syndrome. This paper demonstrated that Nelson syndrome is not simply incidental growth of a pre-existing adenoma but an inevitable result of tumor growth driven by the surgical intervention of adrenalectomy.

In the 1970s–80s, with advances in transsphenoidal microsurgery, first-line treatment of Cushing disease shifted from adrenalectomy to direct removal of the pituitary adenoma, and the incidence of Nelson syndrome decreased greatly. However, Nelson syndrome remains an important complication in patients who inevitably undergo bilateral adrenalectomy after failure or recurrence following transsphenoidal surgery. In the 21st century, stereotactic radiosurgery (Gamma Knife, CyberKnife) was introduced for the treatment and prevention of Nelson syndrome, and cytotoxic drugs such as temozolomide began to be used for aggressive pituitary adenomas. Nelson syndrome is currently classified as ICD-10 E24.1 and is recognized as a separate clinical entity distinct from Cushing adenoma.


2. Causes

The root cause of Nelson syndrome is the rapid growth and increased aggressiveness of a pre-existing ACTH-secreting pituitary adenoma that occurs after bilateral adrenalectomy performed in patients with Cushing disease. Underlying Cushing disease is an ACTH-secreting pituitary adenoma, whose growth is suppressed to some degree by negative feedback from cortisol produced by the adrenal glands. When both adrenal glands are removed, the source of cortisol is completely eliminated, and blood cortisol concentrations become extremely low or reach an acortisolemic state.

This loss of cortisol negative feedback causes two important changes at the hypothalamic–pituitary level. First, corticotropin-releasing hormone (CRH) is secreted in large amounts from the hypothalamus without inhibition, continuously stimulating pituitary corticotroph cells. Second, the pituitary adenoma cells themselves are freed from inhibition by cortisol and become more sensitive to proliferative stimuli. Through the synergy of these two effects, an ACTH-secreting adenoma that was previously a microadenoma rapidly grows into a macroadenoma, and the biological aggressiveness of the tumor also increases, so that it can invade surrounding structures (cavernous sinus, optic chiasm, skull base).

As a result of adenoma growth, together with ACTH, α-MSH (melanocyte-stimulating hormone) and β-MSH, metabolic products of its precursor protein pro-opiomelanocortin (POMC), are also secreted in large amounts. Melanin pigment synthesis is excessively stimulated via the MC1R (melanocortin 1 receptor) and MC2R receptors on melanocytes, producing characteristic hyperpigmentation of the skin and mucosa throughout the body. Unlike simple sunburn or the pigmentation of Addison disease, this hyperpigmentation shows a distribution pattern that is more marked in specific sites such as the palmar creases, oral mucosa, scars, and nipples.

Known risk factors for the development of Nelson syndrome include a higher baseline plasma ACTH before adrenalectomy, younger age at adrenalectomy, absence of pituitary radiotherapy before adrenalectomy, and a pituitary adenoma underlying Cushing disease that had aggressive characteristics from the outset.


3. Genetics

Because Nelson syndrome results from the growth and increased aggressiveness of a pre-existing Cushing adenoma, its genetic background is shared with Cushing disease adenomas. USP8 somatic mutations, the most common finding in Cushing adenomas, are also found in adenomas that progressed to Nelson syndrome. However, some studies have presented evidence that adenomas that transformed into Nelson syndrome acquire additional genomic abnormalities (chromosomal instability, loss of heterozygosity) compared with Cushing adenomas, suggesting that secondary somatic mutations may contribute to the transition to aggressive growth.

Studies report differing results on the relationship between USP8 mutations and the risk of developing Nelson syndrome. Some studies report a lower risk of Nelson syndrome in Cushing adenomas with USP8 mutations, whereas others report no difference. This may be due to limited sample sizes and differences in follow-up duration, and no clear conclusion has yet been reached.

Associations with cell-cycle regulatory genes are also being explored. Abnormal expression of CDKN2A (p16), RB1 (retinoblastoma 1), PTTG1, and others is frequently observed in aggressive pituitary adenomas, and these molecular characteristics may help explain the rapid tumor proliferation in Nelson syndrome. There are also clinical study results showing that Cushing adenomas with a high Ki-67 proliferation index have a higher risk of progressing to Nelson syndrome after adrenalectomy.

Nelson syndrome itself is not a hereditary disease and is not passed from parents to children. Association with MEN1 or other hereditary tumor syndromes is a matter to be considered already at the Cushing adenoma stage. Additional genetic testing of family members of patients with Nelson syndrome is in principle unnecessary. However, when it occurs at a young age or is accompanied by multiple endocrine abnormalities, it is appropriate to exclude a genetic background such as MEN1.


4. General epidemiology

Nelson syndrome is a rare complication defined by a specific prior treatment, occurring only in patients with Cushing disease who have undergone bilateral adrenalectomy. Its incidence is reported at about 8–38% after bilateral adrenalectomy depending on the study, and this wide range reflects differences in follow-up duration, diagnostic criteria, and whether radiotherapy was performed before adrenalectomy. The incidence is highest when adrenalectomy is performed without radiotherapy, and there are reports that prior radiotherapy reduces the incidence to about half or less.

The time to onset of Nelson syndrome after adrenalectomy is mostly 1–4 years, but reports range widely from several months to more than 20 years. This wide range of onset emphasizes the need for long-term follow-up. Studies show that the higher the baseline ACTH before adrenalectomy and the younger the age at adrenalectomy, the higher the risk of Nelson syndrome. In particular, after bilateral adrenalectomy performed in children, faster adenoma growth tends to be observed than in adults.

In the late 20th century, as transsphenoidal surgery became established as the first-line treatment for Cushing disease, the absolute number of patients undergoing bilateral adrenalectomy decreased, and the number of patients with Nelson syndrome fell sharply accordingly. Nelson syndrome is now a rare complication occurring mainly in patients who chose bilateral adrenalectomy after failure or recurrence following transsphenoidal surgery, and it has become a rare clinical situation encountered once every several years at specialized pituitary centers. In Korea as well, as treatment patterns for Cushing disease have shifted toward transsphenoidal surgery as in Western countries, Nelson syndrome is becoming rare, but accurate domestic epidemiological data are limited.

Regarding sex distribution, because Cushing disease itself has a female predominance, Nelson syndrome is also more common in women. By age, it occurs mainly in the 20s–50s, and in those who underwent this surgery at a younger age, Nelson syndrome may develop over a longer follow-up period after adrenalectomy.


5. Pathophysiology

The pathophysiology of Nelson syndrome can be summarized as disinhibition of the HPA axis caused by abrupt loss of cortisol negative feedback and autonomous growth of the ACTH-secreting adenoma. In the normal HPA axis, blood cortisol acts directly on CRH-secreting cells of the hypothalamus and corticotroph cells of the pituitary to deliver inhibitory signals. The inhibitory signal of cortisol through the glucocorticoid receptor (GR) reduces transcription of the POMC gene and suppresses proliferation of corticotroph cells.

When both adrenal glands are removed, this inhibitory signal is suddenly eliminated. As a result, CRH secretion from the hypothalamus surges, and growth stimulation of pituitary corticotroph cells—particularly the pre-existing ACTH-secreting adenoma cells—increases explosively. Because the adenoma cells of Cushing disease were resistant from the outset to negative feedback via GR, in the absence of cortisol this resistance promotes autonomous proliferation of the adenoma even more markedly.

At the cell-biological level, CRH binds to the CRH receptor (CRHR1) of corticotroph cells, activating the cAMP-PKA signaling pathway and strongly increasing POMC transcription. POMC is then processed by prohormone convertases into ACTH, α-MSH, β-MSH, β-endorphin, and others. In Nelson syndrome, along with rapid proliferation of adenoma cells, this processing is greatly amplified, and ACTH reaches extremely high levels of hundreds to thousands of pg/mL. At the same time, α-MSH and β-MSH are released into the peripheral blood and stimulate MC1R on skin melanocytes, causing generalized hyperpigmentation.

In terms of tumor aggressiveness, Nelson syndrome adenomas have a higher Ki-67 proliferation index than the initial Cushing adenomas, a higher frequency of invasion of surrounding structures (cavernous sinus, clivus, skull base), and a higher postoperative recurrence rate. This means that the biological aggressiveness of the adenoma increases beyond simple growth in size. Some Nelson adenomas meet the WHO criteria for 'aggressive pituitary adenoma', and rarely progress to pituitary carcinoma.


6. Symptoms

The most prominent and characteristic symptom of Nelson syndrome is generalized hyperpigmentation of the skin and mucosa. This results from continuous stimulation of melanocytes by extremely high levels of ACTH and MSH, and it resembles the hyperpigmentation of Addison disease but is often more severe. Pigmentation appears throughout the body but is especially marked in sun-exposed areas, palmar creases, oral mucosa (gums, tongue, buccal mucosa), scar sites, nipples and areolae, and around the genitals. Patients often subjectively notice that their skin has suddenly become much darker.

As the pituitary adenoma enlarges, symptoms due to mass effect appear. Headache is the most common nonspecific symptom and reflects increased intracranial pressure. When the adenoma compresses the optic chiasm, visual field defects occur, typically bitemporal hemianopsia. Invasion of the cavernous sinus may cause diplopia, ptosis, and facial sensory abnormalities due to ocular motor nerve palsy (cranial nerves III, IV, VI). Severe compression of the optic nerve can lead to vision loss or blindness, which is an emergency requiring immediate treatment.

Systemic symptoms include severe fatigue and generalized weakness, attributable to the combined effect of adrenal insufficiency (no adrenal glands) and extremely high ACTH and MSH. Hypotension, hypoglycemia, and hyponatremia due to adrenal insufficiency may accompany them, and there is a risk of adrenal crisis under stress. Interestingly, because there are no adrenal glands, the hypercortisolemic symptoms of Cushing disease (obesity, hypertension, diabetes, etc.) no longer appear, and in some patients new skin changes and headache arising after improvement of Cushing symptoms are what first raise suspicion of Nelson syndrome.


7. Signs

The most characteristic finding on physical examination is generalized skin hyperpigmentation; pigmentation in areas that are not pigmented in normal people (palms, soles, oral mucosa) strongly suggests ACTH/MSH excess. Existing scars or pressure sites appearing darker than the surrounding skin is also characteristic.

If visual field defects (usually bitemporal hemianopsia or superotemporal quadrantanopia) are found on neuro-ophthalmologic examination, immediate imaging is needed. Optic disc pallor on funduscopy indicates chronic optic nerve compression. Abnormal eye movements (facial palsy, diplopia) suggest cavernous sinus invasion.

On laboratory findings, plasma ACTH is extremely elevated at 200 pg/mL or more (often 500–5,000 pg/mL), several to several tens of times higher than ACTH levels in Cushing disease. Serum cortisol is very low or undetectable because there are no adrenal glands, and there is a risk of acute adrenal crisis if cortisol supplements are not taken. Pituitary MRI shows a macroadenoma (diameter 10 mm or more) or invasive adenoma (invasion of the cavernous sinus, skull base). Confirmation of marked adenoma growth compared with previous pituitary MRI is the key finding supporting the diagnosis.


8. Screening

Screening for Nelson syndrome is achieved through systematic long-term follow-up of all patients with Cushing disease who have undergone bilateral adrenalectomy. According to the current recommendations of major endocrinology societies, patients after adrenalectomy should receive the following regular monitoring for at least 10 years (ideally for life).

First, plasma ACTH measurement is performed every 6 months. If ACTH rises markedly from baseline or increases to 200 pg/mL or more, it is regarded as an early sign of Nelson syndrome and pituitary MRI is performed immediately. Changes in adenoma size are followed with pituitary MRI (gadolinium contrast-enhanced dynamic protocol) at least once a year. If an increase in size of 5 mm or more is confirmed within 1 year, active treatment is considered.

Clinically, if rapid worsening of skin hyperpigmentation, new headache, visual abnormalities, or visual field defects occur, an emergency evaluation including ophthalmologic visual field testing, MRI, and ACTH measurement is performed immediately. In particular, vision loss from optic nerve compression can progress rapidly and may be an emergency requiring immediate surgical decompression.

Whether pituitary radiotherapy was performed before adrenalectomy affects the subsequent follow-up plan, and more intensive follow-up is required if radiotherapy was not performed. Regular check-ups related to management of adrenal insufficiency (hydrocortisone, fludrocortisone replacement) should also be carried out in parallel.


9. Diagnosis

The diagnosis of Nelson syndrome consists of three elements: clinical context (history of bilateral adrenalectomy), biochemical evidence, and imaging findings. Definitive diagnostic criteria include: ① a history of bilateral adrenalectomy for Cushing disease, ② marked elevation of plasma ACTH to 200 pg/mL or more (some literature uses 100 pg/mL as the threshold), ③ confirmation of progressive adenoma growth on pituitary MRI.

Plasma ACTH measurement requires a strict specimen handling procedure: blood is drawn at 8 a.m. in the fasting state into a chilled EDTA tube, centrifuged immediately, and stored at -80°C. Extremely high ACTH (200 pg/mL or more) is part of the clinical definition of Nelson syndrome and is not always proportional to adenoma size. In some patients ACTH reaches tens of thousands of pg/mL.

Direct comparison with previous examinations is essential for pituitary MRI. Adenoma size (largest diameter), degree of cavernous sinus invasion (Knosp grade), distance from the optic chiasm, and presence of optic nerve or chiasm compression should be evaluated systematically. Ophthalmologic visual field testing (automated perimetry, Humphrey visual field test) quantifies the degree of visual impairment and plays an important role in deciding on surgery. When skull base invasion is suspected, bone invasion is further evaluated with CT. In rare cases where systemic metastasis is suspected (differentiation of pituitary carcinoma), FDG-PET CT is used.


10. Treatment

First-line treatment of Nelson syndrome is adenoma removal by transsphenoidal surgery. However, Nelson syndrome adenomas are often large invasive adenomas that are difficult to resect completely, and the postoperative recurrence rate is higher than for typical Cushing adenomas. The main goals of surgery are relief of optic nerve compression (preservation of vision), minimization of tumor volume, and lowering of ACTH levels. Surgery by an experienced pituitary neurosurgeon is recommended.

For residual or recurrent disease after surgery, stereotactic radiosurgery (Gamma Knife radiosurgery, GKS) is an important second-line treatment. It is applicable when the adenoma is located at a sufficient distance from the optic nerve (generally 3–5 mm or more), and normalization of ACTH levels and suppression of adenoma growth have been reported. The remission rate is about 25–50%, and it takes months to years for the effect to appear. When the adenoma is close to the optic nerve or large in volume, fractionated radiotherapy is chosen.

As drug treatment, the somatostatin receptor ligand pasireotide shows effects in suppressing ACTH secretion and adenoma growth. The dopamine agonist cabergoline has also been reported to be effective in some patients. When the adenoma has become aggressive or progressed to pituitary carcinoma, the alkylating chemotherapeutic agent temozolomide (oral, once weekly or 5/28-day regimen) is the only cytotoxic agent with proven efficacy. The response rate is higher when MGMT (O6-methylguanine-DNA methyltransferase) expression is low. Management of adrenal insufficiency with hydrocortisone and fludrocortisone is essential throughout all treatment.

From a preventive standpoint, when bilateral adrenalectomy is unavoidable in Cushing disease, performing pituitary radiotherapy before adrenalectomy can lower the risk of Nelson syndrome by about half.


11. Prognosis

The prognosis of Nelson syndrome is generally worse than that of typical Cushing adenomas. This is because the adenomas are often found as large invasive forms, complete surgical resection is difficult, and recurrence rates are high. Complete remission after surgery (normalization of ACTH and negative imaging findings) is reported to be achieved in 30–50%, but recurrence is frequent on long-term follow-up.

The most serious complication is vision loss; irreversible visual field defects or blindness can occur due to compression of the optic nerve or optic chiasm. Vision can recover if compression is relieved by early surgery, but recovery is difficult if treatment is delayed. Cranial nerve palsies due to cavernous sinus invasion (diplopia, ptosis, facial sensory abnormalities) also cause serious functional impairment. In rare cases of progression to pituitary carcinoma, spinal and systemic metastases can occur, and the prognosis is extremely poor.

With early detection, that is, when the adenoma is found before it becomes large through regular ACTH and MRI follow-up after adrenalectomy, the surgical success rate is high and neurological complications can be prevented. A multidisciplinary approach including radiotherapy (endocrinology, neurosurgery, radiation oncology, ophthalmology) is essential for the best outcomes. Management of adrenal insufficiency and the adequacy of cortisol replacement also have an important effect on overall prognosis and quality of life.


12. Prevention

The most effective prevention of Nelson syndrome is to eliminate the need for bilateral adrenalectomy by successfully performing transsphenoidal surgery as first-line treatment of Cushing disease. Referring the initial surgery to an experienced pituitary neurosurgeon is the most important preventive strategy.

When bilateral adrenalectomy cannot be avoided, there are cohort study results showing that pituitary radiotherapy before adrenalectomy (Gamma Knife or fractionated radiotherapy) can lower the risk of Nelson syndrome by about half. However, radiotherapy takes years to take effect, and if adrenalectomy is performed in the meantime, the effect may be incomplete. Therefore, radiotherapy before adrenalectomy is considered as 'prophylactic radiotherapy', and it is recommended particularly when baseline ACTH before adrenalectomy is high.

Long-term follow-up with ACTH measurement every 6 months and annual pituitary MRI in all patients after adrenalectomy is key to early detection of Nelson syndrome (secondary prevention). With early detection, surgery is possible while the adenoma is small and it becomes eligible for radiosurgery, greatly improving the prognosis. Educating patients to visit a specialized center immediately if rapid worsening of skin hyperpigmentation, headache, or visual abnormalities occur is also an important preventive activity.


13. References

  1. Nelson DH, Meakin JW, Thorn GW. ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome. Ann Intern Med. 1960;52:560–569. doi:10.7326/0003-4819-52-3-560 PMID: 13837972
  2. Assié G, Bahurel H, Coste J, et al. Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's syndrome. J Clin Endocrinol Metab. 2007;92(1):172–179. doi:10.1210/jc.2006-1328 PMID: 17032714
  3. Nagesser SK, van Seters AP, Kievit J, Hermans J, van Dulken H, Krans HM. Long-term results of total adrenalectomy for Cushing's disease. World J Surg. 2000;24(1):108–113. doi:10.1007/s002689910019 PMID: 10594215
  4. Jenkins PJ, Trainer PJ, Plowman PN, et al. The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab. 1995;80(1):165–171. doi:10.1210/jcem.80.1.7530254 PMID: 7530254
  5. Kemink SA, Grotenhuis JA, De Vries J, Pieters GF, Hermus AR, Smals AG. Management of Nelson's syndrome: observations in fifteen patients. Clin Endocrinol (Oxf). 2001;54(1):45–52. doi:10.1046/j.1365-2265.2001.01166.x PMID: 11167924
  6. Barber TM, Adams E, Ansorge O, Byrne JV, Karavitaki N, Wass JA. Nelson's syndrome. Eur J Endocrinol. 2010;163(4):495–507. doi:10.1530/EJE-10-0466 PMID: 20639355
  7. Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93(7):2454–2462. doi:10.1210/jc.2007-2734 PMID: 18413427
  8. Fountas A, Lim ES, Drake WM, et al. Outcomes of patients with Nelson's syndrome after primary treatment: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105(7):e2638–e2648. doi:10.1210/clinem/dgaa213 PMID: 32313949
  9. Moyes VJ, Alusi G, Sabin HI, et al. Treatment of Nelson's syndrome with temozolomide. Eur J Endocrinol. 2009;160(1):115–119. doi:10.1530/EJE-08-0557 PMID: 18953012
  10. Reincke M, Hahner S, Beuschlein F. Management of adrenal tumors: a review of current therapies. Endocr Rev. 2021;42(6):1–22. doi:10.1210/endrev/bnab003 PMID: 33486540